Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.vijayadiagnostic.com | |
Market Cap | 4,311.41 Cr. | |
Enterprise Value(EV) | 4,146.68 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 8.80 | Trailing Twelve Months Ending 2022-09 |
Price-Earning Ratio (PE) | 48.03 | Trailing Twelve Months Ending 2022-09 |
Industry PE | 46.37 | Trailing Twelve Months Ending 2022-09 |
Book Value / Share | 49.03 | Trailing Twelve Months Ending 2022-09 |
Price to Book Value | 8.62 | Calculated using Price: 422.40 |
Dividend Yield | 0.24 | Period Ending 2022-03 |
No. of Shares Subscribed | 10.21 Cr. | 102,069,262 Shares |
FaceValue | 1 | |
Company Profile | ||
The company is one of the fastest-growing diagnostic chains in Southern India. It offers a one-stop solution for pathology and radiology testing services. |
1 Day |
|
+0.57% |
1 Week |
|
+2.82% |
1 Month |
|
-1.25% |
3 Month |
|
-10.77% |
6 Month |
|
+14.13% |
1 Year |
|
-17.81% |
2 Year |
|
|
5 Year |
|
|
10 Year |
|
4 years | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 22.58 | 26.07 | 26.91 | 26.85 | |
Return on Capital Employed (%) | 31.56 | 35.47 | 37.97 | 39.37 | |
Return on Assets (%) | 11.42 | 14.11 | 16.76 | 17.85 |
Particulars | 5 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 207 | 275 | 359 | 468 | 500 | |
Non Curr. Liab. | 141 | 148 | 132 | 169 | 215 | |
Curr. Liab. | 57 | 59 | 44 | 66 | 73 | |
Minority Int. | 0 | 0 | 0 | 1 | 2 | |
Equity & Liab. | 405 | 481 | 535 | 705 | 791 | |
Non Curr. Assets | 268 | 294 | 296 | 435 | 519 | |
Curr. Assets | 137 | 186 | 239 | 270 | 272 | |
Misc. Exp. not W/O | ||||||
Total Assets | 405 | 481 | 535 | 705 | 791 |
Particulars | 5 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
Net Sales | 293 | 339 | 377 | 462 | 452 | |
Other Income | 10 | 15 | 12 | 13 | 12 | |
Total Income | 303 | 354 | 389 | 475 | 465 | |
Total Expenditure | -184 | -206 | -211 | -259 | -268 | |
PBIDT | 118 | 148 | 178 | 217 | 197 | |
Interest | -14 | -15 | -15 | -16 | -18 | |
Depreciation | -40 | -49 | -50 | -53 | -58 | |
Taxation | -19 | -21 | -27 | -37 | -30 | |
Exceptional Items | ||||||
PAT | 46 | 63 | 85 | 111 | 90 | |
Minority Interest | -1 | -1 | -1 | |||
Share Associate | ||||||
Other Related Items | ||||||
Consolidated Net Profit | 46 | 63 | 84 | 110 | 90 | |
Adjusted EPS | 102 | 138 | 8 | 11 | 9 |
Particulars | 4 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 91 | 106 | 130 | 158 | |
Cash Fr. Inv. | -90 | -31 | -130 | -123 | |
Cash Fr. Finan. | -7 | -30 | -49 | -31 | |
Net Change | -7 | 46 | -49 | 4 | |
Cash & Cash Eqvt | 10 | 56 | 7 | 11 |
Thu, 02 Feb 2023
Board Meeting Intimation for Approval Of Unaudited Financial Results (Standalone & Consolidated) For The Quarter And Nine Months Ended 31/12/2022 Vijaya Diagnostic Centre Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2023 inter alia to consider and approve 1. The Unaudited Financial Results (both Standalone and Consolidated) for the third quarter and nine months ended 31st December 2022; and2. Other Corporate Matters. |
Mon, 09 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 We hereby certify that the details of securities dematerialized/rematerialized during the quarter ended December 31 2022 as required under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 have been furnished to all the stock exchanges where the shares of the Company are listed. The letter confirming the same from our RTA - KFin Technologies Limited dated January 04 2023 is enclosed for your reference. Further the securities comprised in the said certificate if any have been listed on the Stock Exchanges where earlier issued securities of the Company were listed. |
Mon, 09 Jan 2023
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby give the following details of the proposed schedule of Analyst / Institutional Investor meeting with the Company:Date of Meeting: January 10 2023Event: Group Meeting with AnalystsType of the Meeting: Physical MeetingVenue of the Meeting: Registered Office Hyderabad. |
Thu, 02 Feb 2023 |
|
|
|
|
|